Opko Health Acquires NK-1 Compounds From Schering

Opko Health has completed the acquisition of rolapitant and a related compound from Schering Corporation, a subsidiary of Merck & Co (Schering).

Rolapitant, a neurokinin-1 (NK-1) receptor antagonist, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.

NK-1 receptors are highly concentrated in the brain and are also found in other tissues of the body. Activation of NK-1 receptors leads to the release of neurotransmitters and other signaling molecules that play a central role in controlling nausea and vomiting and other basic functions.

The company has also initiated Phase I clinical testing for a second compound in the same class. It is anticipated that these compounds may have advantages over presently marketed products.

Phillip Frost, chairman and CEO of Opko, said: “We are pleased to complete the acquisition of these valuable assets from Schering, and we look forward to rapidly completing development of rolapitant, the most advanced project among the assets acquired.”